Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Many protein kinases are validated intervention points for drug development, however active site similarities often lead to a lack of selectivity and unwanted side effects in the clinic. To address this issue, it is desirable to increase the number of high resolution crystal structures and complexes with non-adenosine ligands available for the rational design of more selective inhibitors. Recent progress in protein crystallography and biotechnology has enabled structural genomics projects to target challenging proteins successfully, including protein kinases. As we discuss here, this effort has resulted in a considerable increase in the number of available high resolution structures and inhibitor complexes and has identified novel structural motifs that are available for drug development.

Original publication




Journal article


Drug discovery today

Publication Date





365 - 372


University of Oxford, Structural Genomics Consortium, Botnar Research Centre, Nuffield Othopaedic Centre, Old Road, Oxford, OX3 7LD, UK.


Humans, Protein Kinase Inhibitors, Technology, Pharmaceutical, Genomics, Drug Design, Models, Molecular